spacer
home > ebr > winter 2002 > from genes to drugs
PUBLICATIONS
European Biopharmaceutical Review

From Genes to Drugs

One of the biggest obstacles in the development of cancer therapeutics is the sheer complexity of the problem. Cancer may result from a large number of genetic and molecular defects, or combination of these defects, giving rise to loss of cell cycle checkpoints and unregulated cell division. Even individual tumours may exhibit heterogeneous phenotypes at the cellular level. The inherent genetic instability of cancer cells may also add to the problem, enabling them to continue to change during treatment and effectively presenting a moving target.The majority of anti-cancer therapeutics currently in use were discovered due to their ability to kill fast-growing cancer cells. Unfortunately, these often cause severe side effects due to their impact on other fast-growing cells in the body. There is, therefore, a need to design drugs that target a specific pathogenic pathway and to base the design of the drug upon the structure of its protein target.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Bob Jackson, Executive Director of R&D at Cyclacel Dr Robert Jackson joined Cyclacel in January 2001. Prior to this he was Research and Development Director at Celltech Group plc and Executive Director, R&D and Chief Operating Officer at Chiroscience Group plc.
Before these appointments, Dr Jackson was Vice President of R&D at Agouron Pharmaceuticals and headed cancer research at DuPont Pharmaceuticals and Warner-Lambert Company. Dr Jackson has been instrumental in the discovery and development of several marketed drugs used to treat cancer, HIV and other serious diseases. He holds a BA from the University of Cambridge and a PhD from the University of London, Institute of Cancer Research.

spacer
Dr Bob Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Applikon Biotechnology launches fully customizable single-use bioreactor using 3D printing technology

Dutch-based upstream bioprocess equipment specialist Applikon Biotechnology B.V. (Applikon) has launched the single-use AppliFlex ST lab-scale bioreactor as a significant extension to its range of innovative bioreactor systems. AppliFlex ST is a fully customizable and scalable stirred tank single-use bioreactor that uses 3D printing technology to provide a head plate that is uniquely configured to each individual process, including custom impeller design, and different sample port connections.
More info >>

White Papers

Spotlight on Quality in Study Startup

Oracle Health Sciences

This white paper addresses the growing interest in quality in clinical trial execution and how workflows play an essential role by building in the steps needed to comply with TMF guidelines, reducing downstream problems. This proactive strategy limits issues caused by siloes, yielding process improvements measurable by performance metrics.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement